Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy

Acta Pharmacologica Sinica

Volumn 25, Issue 12, 2004, Pages 1576-1583

  Jiang, De Chun ^a   Wang, Li ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Bayes theorem; Epilepsy; Pharmacokinetics; USC*PACK software; Valproic acid

Indexed keywords

VALPROIC ACID;

ACCURACY; ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CHILD; CHINESE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL;

ADOLESCENT; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MODELS, THEORETICAL; RANDOM ALLOCATION; VALPROIC ACID;

EID: 10344222132     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bourgeois BFD. Antiepileptic drugs in pediatric practice. Epilepsia 1995; 36: S34-45.
2. Davis R, Peters DV, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-72.
3. Bourgeois BFD. Valproic acid: Clinical use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs. New York: Raven Press; 1995. p 633-9.
4. Yu LY, Qu ZP, Hong Z, Zhang JJ. Syrup sodium valproate in treatment of epilepsy relationship of dose, blood level and effect. Clin Pharm 1995; 4: 4-7.
5. Hou Q, Qu ZP, Yu LY, Zhang JH, Wu YL, Zhang H. Pharmacokinetics, serum concentration and therapy efficacy of enteric-coated tablet and sustained release tablet of valproate. Chin J Neurol Psych 1993; 26: 165.
6. Cloyd JC, Fisher JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV: Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993; 53: 22-9.
7. USC*PACK [computer program]. Version 10.7. Los Angeles. CA: Laboratory of Applied Pharmacokinetics, University of Southern California. School of Medicine: USC*PACK P.C. Collection Clinical Research Programs. 1995.
8. Charpiat B, Breant V, Pivot-Dumarest C, Maire P, Jelliffe RW. Prediction of Future Serum Concentrations with Bayesian Fitted Pharmacokinetic Models: Results with Data Collected by Nurses Versus Trained Pharmacy Residents. Ther Drug Monit 1994; 16: 166-73.
9. Jelliffe RW The USC*PACK PC User Manual. The program NPEM2 (version 3.0) from the Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine, CSC 134-B, 2250 Alcazar St, Los Angeles CA 90033. 1995.
10. Sun H, Fadiran EO, Jones CD, Lesko L, Hung SM, Higgins K, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37: 41-58.
11. Charpiat B, Falconi I, Breant V, Jelliffe RW, Sab JM, Ducerf C, et al. A population pharmacokinetic model of cyclosporine in the early postoperative phase with liver transplants, and its predictive performance with Bayesian fitting. Ther Drug Monit 1998; 20: 158-64.
12. Jelliffe RW, Schumitzky A, Van Guilder, Liu M, Hu L, Maire P, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380-93.
13. Bruni J, Wilder BJ, Willmore LJ, Perchalski RJ, Villarreal HJ. Steady-state kinetics of valproic acid in epileptic patients. Clin Pharmacol Ther 1978; 24: 324-32.
14. Puentes E, Puzantian T, Lum BL. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit 1999; 21: 351-4.
15. Macchi-Andanson M, Charpiat B, Jelliffe RW, Ducerf C, Fourcade N, Baulieux J. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129-33.
16. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
17. Charpiat B, Breant V. Another suggestion for measuring predictive performance for aminoglycoside therapy. Int J Biomed Compt 1994; 36: 161-2.
18. Breant V, Charpiat B, Sab J, Maire P, Jelliffe R. How many patients and blood levels appear needed for population pharmacokinetic analysis? A study with a one-compartment model applied to cyclosporine. Eur J Clin Pharmacol 1996; 51: 283-8.
19. Dodge W, Jelliffe RW, Richardson J, McCleery RA, Hokanson JA, Snodgrass WR. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther 1991; 50: 25-31.
20. Kisor D, Watling S, Zarowitz B, Jelliffe RW. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximization (NPEM) algorithm. Clin Pharmacokinet 1992; 23: 62-8.
21. Hou Q, Qu ZP, Yu LY, Zhang JH, Wu YL. Clinical pharmacokinetics and therapy efficacy of enteric-coated tablet of valproate. Chin J Nerv Ment Dis 1993; 19: 249-50.
22. Zhong SL, Feng SH, Jiang YP, Wu SCl. Determination of pharmacokinetic parameters of valproate in epileptic children. J Appl Clin Pediat 1995; 10: 163-4.
23. Wang L. Drugs on central nervous system. In: Wang L. Pediatric Pharmacology and Drug Therapeutics. Beijing: Beijing Medical University Press, 2002: 210-2.
24. Huang SP, He GZ, Chen ZQ, Li RL, He J, Wang JQ, et al. Research of pharmacokinetics and steady state concentration of valproate in epileptic children. Chin J Pediatr 1994; 32: 89-91.
25. Puentes E, Puzantian T, Lum BL. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit 1999; 21: 351-4.
26. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21: 736-43.
27. Mihaly GW, Vajda FJ, Miles JL. Single and chronic dose pharmacokinetics of sodium valproate in epileptic patients. Eur J Clin Pharmacol 1979; 16: 23-9.
28. Zheng HL, Liu WD, Qi YM, Yang Y, Huang XS, Jing XY, et al. Research of serum concentration of valproate treatment in different age epileptic patients. J Appl Clin Pediatr 1995; 10: 168.
29. Serrano BB, Buelga DS, Otero MJ, Otero MJ, Buelga DS, Serrano J, et al. Population estimation of valproic acid clearance in adult patients' using routine clinical pharmacokinetic data. Biopharm Drug Dispos 1999; 20: 233-40.
30. Yukawa EJ, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997; 37: 1160-7.
31. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet 1996; 31: 470-93.
32. Pokrajac M, Miljkovic B, Varagic VM, Levic Z. Pharmacokinetic interaction between valproic acid and phenobarbital. Biopharm Drug Dispos 1993; 14: 81-6.
33. Kondo T, Otani K, Hirano T, Kaneko S, Fukushima Y. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Pharmacol 1990; 29: 116-9.
34. Lugo G, Castaneda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997; 19: 271-6.